Vertex: Rote Zahlen im zweiten Quartal - 500 Beiträge pro Seite

[Nachrichten [wO]]

Ohne Akquisitions-Kosten hat Vertex im abgelaufenen Quartal einen Verlust von 9,4 Mio.$ bzw. 16 Cent je Aktie erwirtschaftet. Im Vorjahresquartal war es noch ein Gewinn von 2,6 Mio.$ bzw. 4 Cent je Aktie. Die Umsätze sind auf 21,4 Mio.$ zurück gegangen. Der Löwenanteil des Umsatzes geht auf Tantiemen Produktverkäufe sowie Zahlungen aus Kooperationen zurück.

Im April hat Vertex die Übernahme von Aurora Bioscience gemeldet. Der Kaufpreis beträgt 592 Mio.$. Vertex notiert aktuell 1,6 Prozent über dem Vortagsniveau.

Autor: Alexander Apel (© wallstreet:online AG),16:44 27.07.2001

[Stinking_Rich]

ein super Beispiel wie man auch solche Meldungen durch den Dreck ziehen kann.
Die Zahlen sind zwar nicht überwältigend aber...

...warum habt ihr bloß vergessen zu erwähnen das Analysten einen Verlust von 27 Cent erwartet hatten.

..."Die Umsätze sind auf 21,4 Mio.$ zurück gegangen."
ja nur von wieviel lasst ihr auch dezent unter den Tisch fallen.

Eure WO Postings sind manchmal echt peinlich.

[dosto]

Vertex Pharmaceuticals Incorporated
2001 Second Quarter Results

Consolidated Statement of Operations Data
(In thousands, except per share amounts)
(Unaudited)

Three Months Ended Six Months Ended
June 30, June 30,
2001 2000* 2001 2000*
Revenues:
Royalties and
product sales $2,767 $3,303 $5,280 $5,922
Collaborative and
other research
and development
revenues 18,676 23,720 35,220 29,233

Total revenues $21,443 $27,023 $40,500 $35,155

Costs and expenses:
Royalties and
product costs $921 $1,100 $1,758 $1,972
Research and
development 27,794 19,824 53,913 38,428
Sales, general
& administrative 7,518 6,462 15,014 13,039
Other income, net (5,341) (2,965) (11,866) (5,336)

Total costs and
expenses excluding
merger related costs $30,892 $24,421 $58,819 $48,103

Net income (loss)
before cumulative
effect of change in
accounting principle
and merger related
costs $(9,449) $2,602 $(18,319) $(12,948)

Cumulative effect of
change in accounting
principle (Note 1) --- --- --- $(3,161)

Merger related costs
(Note 2) $(2,658) --- $(2,658) ---

Basic net income (loss)
per share before
cumulative effect
of change in
accounting principle
and merger related
costs $(0.16) $0.05 $(0.30) $(0.25)

Diluted net income
(loss) per share
before cumulative
effect of change
in accounting
principle and merger
related costs $(0.16) $0.04 $(0.30) $(0.25)

Basic weighted average
number of common
shares outstanding
(Note 4) 60,337 52,636 60,175 52,283

Diluted weighted
average number of
common shares
outstanding (Note 4) 60,337 58,946 60,175 52,283

*Prior period amounts have been restated in accordance with SAB 101. See Note 1.

Note 1: The cumulative effect of change in accounting principle is a one- time non-cash charge relating to Vertex`s adoption of SAB 101. SAB 101 was issued by the Securities and Exchange Commission ("SEC") in December 1999. SAB 101 provides guidance related to revenue recognition policies based on interpretations and practices followed by the SEC. The impact of Vertex`s adoption of SAB 101 was to defer revenue recognition for certain portions of revenue previously recognized by Vertex under its collaborative agreements into future accounting periods.

Note 2: Merger related costs represent costs associated with the acquisition of Aurora Biosciences Corporation.

Note 3: Net income (loss), including cumulative effect of change in accounting principle and merger related costs, for the three months ended June 30, 2001 and June 30, 2000, was ($12,107), or ($0.20) per basic and diluted share, and $2,602, or $0.04 per diluted share, respectively. Net income (loss), including cumulative effect of change in accounting principle and merger related costs, for the six months ended June 30, 2001 and June 30, 2000 was ($20,977), or ($0.35) per basic and diluted share, and ($16,109), or ($0.31) per basic and diluted share, respectively.

Note 4: Shares used in computing basic and diluted net loss per share have been restated to give effect to the August 23, 2000 two-for-one stock split.

Vertex Pharmaceuticals Incorporated
2001 Second Quarter and Six Month Results

Condensed Consolidated Balance Sheet Data
(In thousands)

June 30, December 31,
2001 2000
(Unaudited)

Assets
Cash and cash equivalents $168,527 $322,090
Short-term investments 151,501 66,509
Other current assets 10,446 14,587
Total current assets 330,474 403,186

Long-term investments 355,427 318,825
Property, plant and equipment, net 43,534 28,149
Other noncurrent assets 37,399 22,721
Total assets $766,834 $772,881

Liabilities and Equity
Current liabilities $38,852 $38,671
Long-term obligations 346,633 347,313
Stockholders` equity 381,349 386,897
Total Liabilities and Equity $766,834 $772,881

was soll daran auch berauschend sein die company burnt money
und zwar erheblich.
schau mal die neuen current assets an.